Case 1 Extra Credit

Ryan Hastings

2/24/2021

Table 1:

Table 1.		
	Digoxin	Placebo
trtmt	1	0
N	3,397	3,403
Age (yr) - mean	63.4	63.5
Age (yr) - SD	11	10.8
Ejection fraction - mean	28.6	28.4
Ejection fraction - SD	8.8	8.9
Median duration of CHF - mo	17	16
Female Sex	22.2	22.5
Nonwhite Race	14.3	14.8
Age > 70 yr	26.7	27.4
Method - ventriculography	65	64.2
Method - echocardiography	29.5	30
Method - angiography	5.5	5.8
Cardiothoracic ratio >0.55	34.6	34.4
NYHA class - I	13.7	13
NYHA class - II	53.3	54.5
NYHA class - III	30.7	30.5
NYHA class - IV	2.2	1.9
No. of signs - 0	1.1	1.1
No. of signs - 1	2.4	2
No. of signs - 2	7.1	7.1
No. of signs - 3	9.3	8.6
No. of signs - 4+	80.2	81.2
History - Previous myocardial infarction	64.7	65.3
History - Current anigma	27.1	26.4
History - Diabetes	28.3	28.6
History - Hypertension	45	45.8
Previous digoxin use	44.1	44.6
Cause - Ischemic	70.8	70.5
Cause - Nonischemic	28.9	29.3
Cause - Nonischemic - Idiopathic	15.5	14.2
Cause - Nonischemic - Hypertensive	8	9.1
Cause - Nonischemic - Other	5.5	6
Medications - Diuretics	81.2	82.2
Medications - ACE inhibitors	94.1	94.8
Medications - Nitrates	42.2	43.1
Medications - Other vasodilators	0.9	1.5
Dose - 0.125 mg	17.5	17.4
Dose - 0.250 mg	70.6	70.1
Dose - 0.375 mg	10.3	11.3
Dose - 0.500 mg	1.1	0.9